시장보고서

상품코드

1813969

유도만능줄기세포 생산 시장 규모, 점유율, 동향 분석 보고서 : 프로세스별, 워크플로우별, 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Induced Pluripotent Stem Cells Production Market Size, Share & Trends Analysis Report By Process, By Workflow (Reprogramming, Cell Culture), By Product, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 08월 | 리서치사:

Grand View Research | 페이지 정보: 영문 120 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유도만능줄기세포 생산 시장 요약

세계 인공만능줄기세포 생산 시장 규모는 2024년 16억 2,000만 달러로 추정되며, 2033년에는 37억 8,000만 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 10.01%의 CAGR로 성장할 것으로 예상됩니다.

줄기세포를 이용한 치료법의 가능성, 암 발병률 증가, 줄기세포 연구를 위한 자본 투자, 배아줄기세포(ESC)에 비해 인공만능줄기세포(iPSC)의 여러 장점은 시장 성장을 크게 촉진하고 있습니다.

신약개발 및 독성 스크리닝에서 iPSC 유래 세포의 역할 확대

신약 개발 및 독성 스크리닝에 인공줄기세포(iPSC) 유래 세포의 활용은 iPSC 제작 시장의 주요 성장 요인으로 부상하고 있습니다. 제약회사나 바이오기업들은 기존 세포주나 동물 모델보다 인간의 생리를 잘 모방한 생리학적으로 적합한 in vitro 모델을 만들기 위해 iPSC 유래 심근세포, 간세포, 신경세포를 채택하는 경우가 늘고 있습니다. 이러한 모델은 높은 처리량 스크리닝을 가능하게 하고, 초기 단계의 안전성 및 유효성 평가를 개선하며, 동물실험을 줄이려는 전 세계적인 움직임에 부합하고, 윤리적 및 규제적 기대에 부응하고 있습니다.

지역 대시보드
시장 규모와 예측 및 동향 분석, 2021-2033년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 태국
- 한국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제10장 경쟁 구도

진출 기업
전략 매핑
기업 시장 상황 분석, 2024년
진출 기업 개요
- Lonza
- Axol Bioscience Ltd.
- Evotec
- Hitachi, Ltd.
- REPROCELL Inc.
- Merck KGaA
- Fate Therapeutics
- Thermo Fisher Scientific, Inc.
- StemCellsFactory III
- Applied StemCells, Inc.

KSM 25.09.26

Induced Pluripotent Stem Cells Production Market Summary

The global induced pluripotent stem cells production market size was estimated at USD 1.62 billion in 2024 and is projected to reach USD 3.78 billion by 2033, growing at a CAGR of 10.01% from 2025 to 2033. The potential of stem cell-based therapies, the growing incidence of cancer, capital investments for stem cell-based research, and multiple advantages of induced pluripotent stem cells (iPSCs) over embryonic stem cells (ESCs) are driving the market growth significantly.

Expanding Role of iPSC-Derived Cells in Drug Discovery and Toxicology Screening

The use of induced pluripotent stem cell (iPSC)-derived cells in drug discovery and toxicology screening is emerging as a major growth driver for the iPSC production market. Pharma and biotech companies are increasingly adopting iPSC-derived cardiomyocytes, hepatocytes, and neuronal cells to create physiologically relevant in vitro models that better mimic human biology than conventional cell lines or animal models. These models enable high-throughput screening, improve early-stage safety and efficacy assessments, and align with the global push to reduce animal testing, meeting ethical and regulatory expectations.

Global Induced Pluripotent Stem Cells Production Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global induced pluripotent stem cells production market report based on process, workflow, product, application, end use, and region:

Process Outlook (Revenue, USD Million, 2021 - 2033)
Manual iPSC Production Process
Automated iPSC Production Process
Workflow Outlook (Revenue, USD Million, 2021 - 2033)
Reprogramming
Cell Culture
Cell Characterization/Analysis
Engineering
Others
Product Outlook (Revenue, USD Million, 2021 - 2033)
Instruments/ Devices
Automated Platforms
Consumables & Kits
- Media
- Kits
- Others
Services
Application Outlook (Revenue, USD Million, 2021 - 2033)
Drug Development & Discovery
Regenerative Medicine
Toxicology Studies
Others
End Use Outlook (Revenue, USD Million, 2021 - 2033)
Research & Academic Institutes
Biotechnology & Pharmaceutical Companies
Hospitals & Clinics
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
Latin America
- Brazil
- Argentina
Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
- 1.2.1. Process
- 1.2.2. Workflow
- 1.2.3. Product
- 1.2.4. Application
- 1.2.5. End Use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
- 1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Expanding Role of iPSC Derived Cells in Drug Discovery and Toxicology Screening
  - 3.2.1.2. Growing Adoption of iPSC in Personalized and Precision Medicine
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Stringent process control and regulatory challenges
  - 3.2.2.2. High cost of production
3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis

Chapter 4. Induced Pluripotent Stem Cells Production Market: Process Business Analysis

4.1. Technology Segment Dashboard
4.2. Global Induced Pluripotent Stem Cells Production Market Process, Movement Analysis
4.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Process, 2021 to 2033 (USD Million)
4.4. Manual iPSC Production Process
- 4.4.1. Global Manual iPSC Production Process Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Automated iPSC Production Process
- 4.5.1. Global Automated iPSC Production Process Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Induced Pluripotent Stem Cells Production Market: Workflow Business Analysis

5.1. Workflow Segment Dashboard
5.2. Global Induced Pluripotent Stem Cells Production Market Workflow Movement Analysis
5.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million)
5.4. Reprogramming
- 5.4.1. Global Reprogramming Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Cell Culture
- 5.5.1. Global Cell Culture Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. Cell Characterization/Analysis
- 5.6.1. Global Cell Characterization/Analysis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Engineering
- 5.7.1. Global Engineering Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Others
- 5.8.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Induced Pluripotent Stem Cells Production Market: Product Business Analysis

6.1. Product Segment Dashboard
6.2. Global Induced Pluripotent Stem Cells Production Market Product Movement Analysis
6.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
6.4. Instrument/Devices
- 6.4.1. Global Instrument/Devices Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Automated Platforms
- 6.5.1. Global Automated Platforms Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Consumables & Kits
- 6.6.1. Global Consumables & Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.2. Media
  - 6.6.2.1. Global Media Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.3. Kits
  - 6.6.3.1. Global Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.4. Others
  - 6.6.4.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Services
- 6.7.1. Global Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Induced Pluripotent Stem Cells Production Market: Application Business Analysis

7.1. Sample Type Segment Dashboard
7.2. Global Induced Pluripotent Stem Cells Production Market Application Movement Analysis
7.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
7.4. Drug Development and Discovery
- 7.4.1. Global Drug Development and Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Regenerative Medicine
- 7.5.1. Global Regenerative Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Toxicology Studies
- 7.6.1. Global Toxicology Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Others
- 7.7.1. Global Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Induced Pluripotent Stem Cells Production Market: End Use Business Analysis

8.1. End Use Segment Dashboard
8.2. Global Induced Pluripotent Stem Cells Production Market End Use Movement Analysis
8.3. Global Induced Pluripotent Stem Cells Production Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
8.4. Research & Academic Institutes
- 8.4.1. Global Research & Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Biotechnology & Pharmaceutical Companies
- 8.5.1. Global Biotechnology & Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Hospitals & Clinics
- 8.6.1. Global Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Induced Pluripotent Stem Cells Production Market: Regional Estimates & Trend Analysis by Process, Workflow, Product, Application, & End Use

9.1. Regional Dashboard
9.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
9.3. North America
- 9.3.1. North America Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.2. U.S.
  - 9.3.2.1. Key Country Dynamics
  - 9.3.2.2. Competitive Scenario
  - 9.3.2.3. Regulatory Framework
  - 9.3.2.4. U.S. Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.3. Canada
  - 9.3.3.1. Key Country Dynamics
  - 9.3.3.2. Competitive Scenario
  - 9.3.3.3. Regulatory Framework
  - 9.3.3.4. Canada Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.3.4. Mexico
  - 9.3.4.1. Key Country Dynamics
  - 9.3.4.2. Competitive Scenario
  - 9.3.4.3. Regulatory Framework
  - 9.3.4.4. Mexico Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.4. Europe
- 9.4.1. Europe Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.2. UK
  - 9.4.2.1. Key Country Dynamics
  - 9.4.2.2. Competitive Scenario
  - 9.4.2.3. Regulatory Framework
  - 9.4.2.4. UK Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.3. Germany
  - 9.4.3.1. Key Country Dynamics
  - 9.4.3.2. Competitive Scenario
  - 9.4.3.3. Regulatory Framework
  - 9.4.3.4. Germany Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.4. France
  - 9.4.4.1. Key Country Dynamics
  - 9.4.4.2. Competitive Scenario
  - 9.4.4.3. Regulatory Framework
  - 9.4.4.4. France Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.5. Italy
  - 9.4.5.1. Key Country Dynamics
  - 9.4.5.2. Competitive Scenario
  - 9.4.5.3. Regulatory Framework
  - 9.4.5.4. Italy Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.6. Spain
  - 9.4.6.1. Key Country Dynamics
  - 9.4.6.2. Competitive Scenario
  - 9.4.6.3. Regulatory Framework
  - 9.4.6.4. Spain Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.7. Denmark
  - 9.4.7.1. Key Country Dynamics
  - 9.4.7.2. Competitive Scenario
  - 9.4.7.3. Regulatory Framework
  - 9.4.7.4. Denmark Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.8. Sweden
  - 9.4.8.1. Key Country Dynamics
  - 9.4.8.2. Competitive Scenario
  - 9.4.8.3. Regulatory Framework
  - 9.4.8.4. Sweden Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.4.9. Norway
  - 9.4.9.1. Key Country Dynamics
  - 9.4.9.2. Competitive Scenario
  - 9.4.9.3. Regulatory Framework
  - 9.4.9.4. Norway Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.5. Asia Pacific
- 9.5.1. Asia Pacific Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.2. Japan
  - 9.5.2.1. Key Country Dynamics
  - 9.5.2.2. Competitive Scenario
  - 9.5.2.3. Regulatory Framework
  - 9.5.2.4. Japan Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.3. China
  - 9.5.3.1. Key Country Dynamics
  - 9.5.3.2. Competitive Scenario
  - 9.5.3.3. Regulatory Framework
  - 9.5.3.4. China Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.4. India
  - 9.5.4.1. Key Country Dynamics
  - 9.5.4.2. Competitive Scenario
  - 9.5.4.3. Regulatory Framework
  - 9.5.4.4. India Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.5. Australia
  - 9.5.5.1. Key Country Dynamics
  - 9.5.5.2. Competitive Scenario
  - 9.5.5.3. Regulatory Framework
  - 9.5.5.4. Australia Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.6. Thailand
  - 9.5.6.1. Key Country Dynamics
  - 9.5.6.2. Competitive Scenario
  - 9.5.6.3. Regulatory Framework
  - 9.5.6.4. Thailand Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.5.7. South Korea
  - 9.5.7.1. Key Country Dynamics
  - 9.5.7.2. Competitive Scenario
  - 9.5.7.3. Regulatory Framework
  - 9.5.7.4. South Korea Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.6. Latin America
- 9.6.1. Latin America Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.2. Brazil
  - 9.6.2.1. Key Country Dynamics
  - 9.6.2.2. Competitive Scenario
  - 9.6.2.3. Regulatory Framework
  - 9.6.2.4. Brazil Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.6.3. Argentina
  - 9.6.3.1. Key Country Dynamics
  - 9.6.3.2. Competitive Scenario
  - 9.6.3.3. Regulatory Framework
  - 9.6.3.4. Argentina Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
9.7. MEA
- 9.7.1. MEA Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.2. South Africa
  - 9.7.2.1. Key Country Dynamics
  - 9.7.2.2. Competitive Scenario
  - 9.7.2.3. Regulatory Framework
  - 9.7.2.4. South Africa Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.3. Saudi Arabia
  - 9.7.3.1. Key Country Dynamics
  - 9.7.3.2. Competitive Scenario
  - 9.7.3.3. Regulatory Framework
  - 9.7.3.4. Saudi Arabia Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.4. UAE
  - 9.7.4.1. Key Country Dynamics
  - 9.7.4.2. Competitive Scenario
  - 9.7.4.3. Regulatory Framework
  - 9.7.4.4. UAE Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 9.7.5. Kuwait
  - 9.7.5.1. Key Country Dynamics
  - 9.7.5.2. Competitive Scenario
  - 9.7.5.3. Regulatory Framework
  - 9.7.5.4. Kuwait Induced Pluripotent Stem Cells Production Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

10.1. Participant Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2024
10.4. Participant's Overview
- 10.4.1. Lonza
  - 10.4.1.1. Overview
  - 10.4.1.2. Financial Performance
  - 10.4.1.3. Product Benchmarking
  - 10.4.1.4. Strategic Initiatives
- 10.4.2. Axol Bioscience Ltd.
  - 10.4.2.1. Overview
  - 10.4.2.2. Financial Performance
  - 10.4.2.3. Product Benchmarking
  - 10.4.2.4. Strategic Initiatives
- 10.4.3. Evotec
  - 10.4.3.1. Overview
  - 10.4.3.2. Financial Performance
  - 10.4.3.3. Product Benchmarking
  - 10.4.3.4. Strategic Initiatives
- 10.4.4. Hitachi, Ltd.
  - 10.4.4.1. Overview
  - 10.4.4.2. Financial Performance
  - 10.4.4.3. Product Benchmarking
  - 10.4.4.4. Strategic Initiatives
- 10.4.5. REPROCELL Inc.
  - 10.4.5.1. Overview
  - 10.4.5.2. Financial Performance
  - 10.4.5.3. Product Benchmarking
  - 10.4.5.4. Strategic Initiatives
- 10.4.6. Merck KGaA
  - 10.4.6.1. Overview
  - 10.4.6.2. Financial Performance
  - 10.4.6.3. Product Benchmarking
  - 10.4.6.4. Strategic Initiatives
- 10.4.7. Fate Therapeutics
  - 10.4.7.1. Overview
  - 10.4.7.2. Financial Performance
  - 10.4.7.3. Product Benchmarking
  - 10.4.7.4. Strategic Initiatives
- 10.4.8. Thermo Fisher Scientific, Inc.
  - 10.4.8.1. Overview
  - 10.4.8.2. Financial Performance
  - 10.4.8.3. Product Benchmarking
  - 10.4.8.4. Strategic Initiatives
- 10.4.9. StemCellsFactory III
  - 10.4.9.1. Overview
  - 10.4.9.2. Financial Performance
  - 10.4.9.3. Product Benchmarking
  - 10.4.9.4. Strategic Initiatives
- 10.4.10. Applied StemCells, Inc.
  - 10.4.10.1. Overview
  - 10.4.10.2. Financial Performance
  - 10.4.10.3. Product Benchmarking
  - 10.4.10.4. Strategic Initiatives

유도만능줄기세포 생산 시장 규모, 점유율, 동향 분석 보고서 : 프로세스별, 워크플로우별, 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Induced Pluripotent Stem Cells Production Market Size, Share & Trends Analysis Report By Process, By Workflow (Reprogramming, Cell Culture), By Product, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033

유도만능줄기세포 생산 시장 요약

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

제4장 유도만능줄기세포 생산 시장 : 프로세스 비즈니스 분석

제5장 유도만능줄기세포 생산 시장 : 워크플로우 비즈니스 분석

제6장 유도만능줄기세포 생산 시장 : 제품 비즈니스 분석

제7장 유도만능줄기세포 생산 시장 : 용도 비즈니스 분석

제8장 유도만능줄기세포 생산 시장 : 최종 용도 비즈니스 분석

제9장 유도만능줄기세포 생산 시장 : 프로세스, 워크플로우, 제품, 용도, 최종 용도별 지역 추정·동향 분석